Interleukin-18 enhances a Th2 biased response and susceptibility to Leishmania mexicana in BALB/c mice

Microbes and Infection

Volumn 10, Issue 7, 2008, Pages 834-839

  Bryson, Karen Jane ^a   Wei, Xiao Qing ^b   Alexander, James ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Interleukin 18; Leishmania mexicana; Th2

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 18;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION SENSITIVITY; LEISHMANIA MEXICANA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN LEISHMANIASIS; SPLEEN CELL; TH2 CELL;

ANIMALS; ANTIBODIES, PROTOZOAN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERLEUKIN-18; INTERLEUKIN-4; LEISHMANIA MEXICANA; LYMPHOCYTES; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; SEVERITY OF ILLNESS INDEX; SKIN; SPLEEN; TH2 CELLS;

ANIMALIA; LEISHMANIA MEXICANA; MUS;

EID: 45849094044     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2008.03.009     Document Type: Article

References (22)

1. Okamura H., Tsutsui H., Kashiwamura S., Yoshimoto T., and Nakanishi K. Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv. Immunol. 70 (1998) 281-312
2. Sugawara I., Yamada H., Kaneko H., Mizuno S., Takeda K., and Akira S. Role of interleukin-18 (IL-18) in mycobacterial infection in IL-18-gene-disrupted mice. Infect. Immun. 67 (1999) 2585-2589
3. Kawakami K., Qureshi M.H., Zhang T., Okamura H., Kurimoto M., and Saito A. IL-18 protects mice against pulmonary and disseminated infection with Cryptococcus neoformans by inducing IFN-gamma production. J. Immunol. 159 (1997) 5528-5534
4. Mastroeni P., Clare S., Khan S., Harrison J.A., Hormaeche C.E., Okamura H., et al. Interleukin 18 contributes to host resistance and gamma interferon production in mice infected with virulent Salmonella typhimurium. Infect. Immun. 67 (1999) 478-483
5. Cai G., Kastelein R., and Hunter C.A. Interleukin-18 (IL-18) enhances innate IL-12-mediated resistance to Toxoplasma gondii. Infect. Immun. 68 (2000) 6932-6938
6. Yoshimoto T., Tsutsui H., Tominaga K., Hoshino K., Okamura H., Akira S., et al. IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 13962-13966
7. + T cells, IL-4 and STAT6. Nat. Immunol. 1 (2000) 132-137
8. Nakanishi K., Yoshimoto T., Tsutsui H., and Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu. Rev. Immunol. 19 (2001) 423-474
9. Wild J.S., Sigounas A., Sur N., Siddiqui M.S., Alam R., Kurimoto M., et al. IFN-gamma-inducing factor (IL-18) increases allergic sensitization, serum IgE, Th2 cytokines, and airway eosinophilia in a mouse model of allergic asthma. J. Immunol. 164 (2000) 2701-2710
10. Xu D., Trajkovic V., Hunter D., Leung B.P., Schulz K., Gracie J.A., et al. IL-18 induces the differentiation of Th1 or Th2 cells depending upon cytokine milieu and genetic background. Eur. J. Immunol. 30 (2000) 3147-3156
11. Wei X.Q., Niedbala W., Xu D., Luo Z.X., Pollock K.G., and Brewer J.M. Host genetic background determines whether IL-18 deficiency results in increased susceptibility or resistance to murine Leishmania major infection. Immunol. Lett. 94 (2004) 35-37
12. Monteforte G.M., Takeda K., Rodriguez-Sosa M., Akira S., David J.R., and Satoskar A.R. Genetically resistant mice lacking IL-18 gene develop Th1 response and control cutaneous Leishmania major infection. J. Immunol. 164 (2000) 5890-5893
13. Ohkusu K., Yoshimoto T., Takeda K., Ogura T., Kashiwamura S., Iwakura Y., et al. Potentiality of interleukin-18 as a useful reagent for treatment and prevention of Leishmania major infection. Infect. Immun. 68 (2000) 2449-2456
14. Mullen A.B., Lawrence C.E., McFarlane E., Wei X.Q., and Carter K.C. Endogenous interleukin-18 is involved in immunity to Leishmania donovani but its absence does not adversely influence the therapeutic activity of sodium stibogluconate. Immunology 119 (2006) 348-354
15. Murray H.W., Tsai C.W., Liu J., and Ma X. Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18. Infect. Immun. 74 (2006) 4370-4374
16. McMahon-Pratt D., and Alexander J. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease?. Immunol. Rev. 201 (2004) 206-224
17. Satoskar A., Bluethmann H., and Alexander J. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect. Immun. 63 (1995) 4894-4899
18. Alexander J., Brombacher F., McGachy H.A., McKenzie A.N., Walker W., and Carter K.C. An essential role for IL-13 in maintaining a non-healing response following Leishmania mexicana infection. Eur. J. Immunol. 32 (2002) 2923-2933
19. Satoskar A., Brombacher F., Dai W.J., McInnes I., Liew F.Y., Alexander J., et al. SCID mice reconstituted with IL-4-deficient lymphocytes, but not immunocompetent lymphocytes, are resistant to cutaneous leishmaniasis. J. Immunol. 159 (1997) 5005-5013
20. Blackwell J.M. Genetic susceptibility to leishmanial infections: studies in mice and man. Parasitology 112 Suppl (1996) S67-S74
21. Padigel U.M., Alexander J., and Farrell J.P. The role of interleukin-10 in susceptibility of BALB/c mice to infection with Leishmania mexicana and Leishmania amazonensis. J. Immunol. 171 (2003) 3705-3710
22. Wershil B.K., Theodos C.M., Galli S.J., and Titus R.G. Mast cells augment lesion size and persistence during experimental Leishmania major infection in the mouse. J. Immunol. 152 (1994) 4563-4571